CAR T cell combination therapies to treat cancer
- PMID: 39059390
- DOI: 10.1016/j.ccell.2024.07.002
CAR T cell combination therapies to treat cancer
Abstract
Chimeric antigen receptor (CAR) T cells are effectively used in certain hematological malignancies, though tumor relapse and limited success in solid tumors persist. Recent efforts focus on developing combination treatments to enhance outcomes and safety. Here, we provide a comprehensive overview of such combinatorial approaches and a consideration of ongoing clinical trials.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests C.H.J. is an inventor on patents and/or patent applications licensed to Novartis Institutes of Biomedical Research and receives license revenue from such licenses. C.H.J. is an inventor on patents and/or patent applications licensed to Kite Pharma, Capstan Therapeutics, Dispatch Therapeutics, and BlueWhale Bio. C.H.J. is a member of the scientific advisory boards of AC Immune, BluesphereBio, BlueWhale Bio, Cabaletta, Carisma, Cartography, Cellares, Celldex, Decheng, Poseida, Replay Bio, Verismo, ViTToria, and WIRB-Copernicus.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
